Albuterol Neb (albuterol nebulizer pediatric)

Albuterol Neb (albuterol nebulizer pediatric) is filed as Short-Acting Beta Agonist. The sections below restate public label fields stored for this profile.

Class
Short-Acting Beta Agonist
Generic name
albuterol nebulizer pediatric
Route
RESPIRATORY (INHALATION)
Dosage forms
HOW SUPPLIED Albuterol Inhalation Solution, USP 0.083% is contained in plastic, sterile, unit dose vials of 3 mL each, supplied in foil pouches: NDC 76420-087-25: carton of 25 vials (relabeled from NDC 0487-9501-25) Storage and Handling PROTECT FROM LIGHT. Store vials in pouch until time of use. Store between 20°C to 25° C (68°F to 77° F), excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Rx Only Relabeled by: Enovachem PHARMACEUTICALS Torrance, CA 90501
Generic available
Yes
Manufacturer
Asclemed USA, Inc.

Approved uses

Albuterol tablets are indicated for the relief of bronchospasm in adults and children 6 years of age and older with reversible obstructive airway disease.

How it works

In vitro studies and in vivo pharmacologic studies have demonstrated that albuterol has a preferential effect on beta 2 -adrenergic receptors compared with isoproterenol. While it is recognized that beta 2 -adrenergic receptors are the predominant receptors in bronchial smooth muscle, data indicate that there is a population of beta 2 -receptors in the human heart existing in a concentration between 10% and 50%. The precise function of these receptors has not been established (see WARNINGS ). The pharmacologic effects of beta-adrenergic agonist drugs, including albuterol, are at least in part attributable to stimulation through beta-adrenergic receptors of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cyclic AMP). Increased cyclic AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. Albuterol has been shown in most controlled clinical trials to have more effect on the respiratory tract, in the form of bronchial smooth muscle relaxation, than isoproterenol at comparable doses while producing fewer cardiovascular effects. Albuterol is longer acting than isoproterenol in most patients by any route of administration because it is not a substrate for the cellular uptake processes for catecholamines nor for catechol- O -methyl transferase.

Warnings and precautions

Albuterol tablets can produce paradoxical bronchospasm, which may be life threatening. If paradoxical bronchospasm occurs, albuterol tablets should be discontinued immediately and alternative therapy instituted.

Contraindications

Albuterol tablets are contraindicated in patients with a history of hypersensitivity to albuterol, or any of its components.

Common side effects

Tremors (20%); Dizziness (7%); Nervousness (4%); Headache (3%); Insomnia (1%); Nausea (4%); Dyspepsia (1%); Nasal congestion (1%)

Adverse reactions

The adverse reactions to albuterol are similar in nature to those of other sympathomimetic agents. Albuterol Tablets Adverse Experience Incidence (% of patients) in Adults and Children 6 Years of Age and Older Adverse Event Percent Incidence Central nervous system Nervousness 20 Tremor 20 Headache 7 Dizziness 2 Weakness 2 Sleeplessness 2 Irritability < 1 Drowsiness < 1 Restlessness < 1 Cardiovascular Palpitations 5 Tachycardia 5 Flushing < 1 Chest discomfort < 1 Musculoskeletal Muscle cramps 3 Gastrointestinal Nausea 2 Genitourinary Difficulty in micturition < 1 Albuterol Extended-release Tablets Incidence of Adverse Reactions (% of Patients) in a 1-week Clinical Trials* Adverse Event Albuterol Extended-release Tablets (4 mg every 12 hours) Albuterol Tablets (2 mg every 6 hours) Nausea 4 4 Nervousness 2 6 Vomiting 2 4 Somnolence 2 2 *This table includes adverse reactions considered to be possibly or probably treatment related in 1-week clinical trial comparing a 4 mg albuterol extended-release tablet administered every 12 hours to a 2 mg albuterol tablet administered every 6 hours. Although not reported for albuterol extended-release tablets in the above study, there have been reports of tremor in other trials. When all clinical experience is considered, the incidence of tremor is approximately the same as that seen with albuterol tablets. A placebo-controlled trial of 4 weeks duration in 157 mild-to-moderate asthmatic children aged 6 to 12 years, demonstrated the safety of escalating doses of albuterol extended-release tablets. In this study, the starting dose of albuterol extended-release tablets was 4 mg twice daily. Patients were advanced to a maximum of 12 mg albuterol extended-release tablets twice daily by the investigator, based on patient tolerance and response. Only one of the 79 children treated with albuterol extended-release tablets was advanced to the maximum daily dose of 12 mg twice daily. The following treatment-related adverse events occurred in more than 5% of treated patients and were greater in albuterol extended-release tablets patients when compared to placebo: Incidence of Adverse Events (% of Patients) in a 4-Week Placebo-Controlled Trial in 157 Children 6 to 12 Years of Age Adverse Event Albuterol Extended-release Tablets % Placebo % Headache 22 9 Nervousness 13 6 Insomnia 11 5 Tremor 10 1 Palpitation 8 1 Tachycardia 8 1 Other adverse events were noted in 5% or fewer patients, or had equal or greater rates of occurrence in placebo patients than in albuterol extended-release tablets patients. Cases of urticaria, angioedema, rash, bronchospasm, oropharyngeal edema and arrhytmias (including atrial fibrillation, supraventricular tachycardia, and extrasystoles) have been reported after the use of albuterol tablets. In addition to those adverse reactions reported above, albuterol, like other sympathomimetic agents, can cause adverse reactions such as angina, central nervous system stimulation, drying or irritation of the oropharynx, hypertension, unusual taste, and vertigo. The reactions are generally transient in nature, and it is usually not necessary to discontinue treatment with albuterol tablets. In selected cases, however, dosage may be reduced temporarily; after the reaction has subsided, dosage should be increased in small increments to the optimal dosage. To report SUSPECTED ADVERSE REACTIONS, contact Amneal Pharmaceuticals at 1-877-835-5472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Dosage and administration

The following dosages of albuterol tablets are expressed in terms of albuterol base.

Drug interactions

The concomitant use of albuterol tablets and other oral sympathomimetic agents is not recommended since such combined use may lead to deleterious cardiovascular effects. This recommendation does not preclude the judicious use of an aerosol bronchodilator of the adrenergic stimulant type in patients receiving albuterol tablets. Such concomitant use, however, should be individualized and not given on a routine basis. If regular coadministration is required, then alternative therapy should be considered.

Common questions

What is Albuterol Neb approved to treat?

According to its FDA label, Albuterol Neb (albuterol nebulizer pediatric) is approved for: Albuterol tablets are indicated for the relief of bronchospasm in adults and children 6 years of age and older with reversible obstructive airway disease. For medical advice, please talk to your prescriber or pharmacist.

What class of drug is Albuterol Neb?

Albuterol Neb (albuterol nebulizer pediatric) belongs to the Short-Acting Beta Agonist class of medications.

What form does Albuterol Neb come in?

The FDA label lists Albuterol Neb (albuterol nebulizer pediatric) as: HOW SUPPLIED Albuterol Inhalation Solution, USP 0.083% is contained in plastic, sterile, unit dose vials of 3 mL each, supplied in foil pouches: NDC 76420-087-25: carton of 25 vials (relabeled from NDC 0487-9501-25) Storage and Handling PROTECT FROM LIGHT. Store vials in pouch until time of use. Store between 20°C to 25° C (68°F to 77° F), excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Rx Only Relabeled by: Enovachem PHARMACEUTICALS Torrance, CA 90501; respiratory (inhalation) route. Available strengths and packaging vary by manufacturer.

Is there a generic version of Albuterol Neb?

Yes. A generic version of Albuterol Neb (albuterol nebulizer pediatric) is available in the U.S. Ask your pharmacist about substitution.

Does Albuterol Neb have a Boxed Warning?

Our ingest of the FDA label for Albuterol Neb (albuterol nebulizer pediatric) does not include a Boxed Warning at this time. See the full label on DailyMed for the current, authoritative version.

How much does Albuterol Neb cost?

Public CMS NADAC pricing for Albuterol Neb (albuterol nebulizer pediatric) is in the range Retail prices vary widely by pharmacy, insurance, and location. Check with your pharmacy or use tools like GoodRx for current pricing.. Retail price varies by pharmacy, insurance, and manufacturer coupons.

Is Albuterol Neb currently under recall?

The FDA Enforcement Report does not show an active/ongoing recall for Albuterol Neb (albuterol nebulizer pediatric) in our latest ingest. Recall data can change daily — verify at FDA.gov.

When was Albuterol Neb approved by the FDA?

The FDA record lists the approval date for Albuterol Neb (albuterol nebulizer pediatric) as 1997-09-17.

Who makes Albuterol Neb?

The FDA label lists Asclemed USA, Inc. as a labeler/manufacturer of Albuterol Neb (albuterol nebulizer pediatric). Multiple firms may market generics of the same molecule.

How should Albuterol Neb be stored?

The FDA label states: "Albuterol tablets, USP; 2 mg of albuterol as the sulfate, are white, round, scored, debossed MP 47 Bottles of 100 NDC 53489-176-01 Bottles of 500 NDC 53489-176-05 Albuterol tablets, USP; 4 mg of albuterol as the sulfate,…" Follow the packaging insert for the authoritative guidance.

What is the pregnancy category for Albuterol Neb?

The FDA label lists a pregnancy category of C for Albuterol Neb (albuterol nebulizer pediatric). Pregnancy and lactation decisions should be made with a clinician.

On this site

Related medications in this class or category

Loading full data from Know Your Drugs Institute…